Exchange: NASDAQ·Updated 04:10 PM EDT
ACOG logo

ACOGAlpha Cognition Inc

$7.89
$0.10
(1.28%)
Today
Closed $7.89
$0.00
(0.00%)
After Hours
EarningsAug 13
Mkt Cap$171.8M
Vol51,970.00
News
all
press releases
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding...
Business Wire
News Placeholder
More News
News Placeholder
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL in Alzheimers Disease
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive...
Business Wire
News Placeholder
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +8.64% and +4.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Alpha Cognition (ACOG) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG: NASDAQ) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported...
Business Wire
News Placeholder
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Wall Street Zen Downgrades Alpha Cognition (NASDAQ:ACOG) to Sell
Wall Street Zen downgraded Alpha Cognition from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
News Placeholder
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial...
Business Wire
News Placeholder
Alpha Cognition (NASDAQ:ACOG) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Alpha Cognition in a research report on Monday...
MarketBeat
News Placeholder
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Alpha Cognition, Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.